Groundbreaking Discoveries in Inflammation and Infection

BioAegis Therapeutics is a clinical stage company, developing novel protein replacement therapies targeted at saving lives. The portfolio is based on the endogenous human protein, plasma gelsolin (pGSN). Plasma gelsolin, recently discovered to be a key component of innate immunity, provides an immunotherapeutic approach to fighting pathogens. Additionally, the protein protects end organs against the effects of an uncontrolled and cascading inflammatory response in numerous diseases.

BioAegis’ assets are directed toward multiple high value indications. Included is a unique, near term opportunity to address the critical, worldwide issue of Antimicrobial Resistance, as pGSN:
• supplements the ability of sub-optimal antibiotics to address infection
• boosts the immune system towards a wide variety of pathogens; and
• addresses the secondary organ damage resulting from uncontrolled infection.
The pristine safety profile is supported by extensive animal research and Phase 1b/2a human clinical trials.